Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to provide written informed consent;~* Male gender at birth;~* Age 15 years and 0 days through 17 years and 364 days, inclusive, at the time of signed informed consent;~* Self reports evidence of high risk for acquiring HIV infection including at least one of the following:~  * At least one episode of unprotected anal intercourse with an HIV-infected male partner or a male partner of unknown HIV status during the last 6 months;~ * Anal intercourse with 3 or more male sex partners during the last 6 months;~ * Exchange of money, gifts, shelter, or drugs for anal sex with a male partner during the last 6 months;~ * Sex with a male partner and has had a sexually transmitted infection (STI) during the last 6 months or at screening;~ * Sexual partner of an HIV-infected man with whom condoms were not consistently used in the last 6 months; or~ * At least one episode of anal intercourse where the condom broke or slipped off during the last 6 months;~* Tests HIV antibody negative at time of screening;~* Willing to provide locator information to study staff;~* Willing to take PrEP;~* Willing to participate in behavioral intervention;~* Reports intention not to relocate out of AMTU study area during the course of the study; and~* Does not have a job or other obligations that would require long absences from AMTU study area (greater than 4 weeks at a time).~Exclusion Criteria:~* Appears visibly distraught or presence of active serious psychiatric symptoms (e.g., active hallucinations, suicidal, homicidal, or exhibiting violent behavior) at the time of consent;~* Intoxicated or under the influence of alcohol or other drugs at the time of consent;~* Any significant uncontrolled, active or chronic disease process that, in the judgment of the site investigator, would make participation in the study inappropriate. (Appropriately managed conditions, like well-controlled diabetes, would not preclude enrollment; the site is encouraged to contact the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 113 Protocol Team if they are having difficulty making the judgment.);~* History of bone fractures not explained by trauma;~* Acute or chronic hepatitis B infection as indicated by positive hepatitis B surface antigen (sAg) test at time of screening;~* Confirmed renal dysfunction (Creatinine Clearance (CrCl) \< 75 ml/min calculated based on bedside Schwartz formula: Glomerular filtration rate (GFR) = (0.413 x (height in centimeters)) / (serum creatinine in mg/dl)), or serum creatinine \> upper limit of normal (ULN), or history of renal parenchymal disease or presence of only one kidney at time of screening;~* Confirmed ≥ Grade 2 hypophosphatemia at time of screening;~* Confirmed ≥ Grade 2 hematologic system abnormality (White Blood Count (WBC), Absolute Neutrophil Count (ANC), hemoglobin, or platelets) at time of screening;~* Confirmed ≥ Grade 2 hepatobiliary system abnormality (Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), or bilirubin) at time of screening;~* Confirmed proteinuria as indicated by urine dipstick result ≥ 1+ at time of screening, regardless of urine protein to creatinine ratio (UP/C);~* UP/C \> 0.37 g/g at time of screening, regardless of urine dipstick protein result;~* Confirmed normoglycemic glucosuria as indicated by urine dipstick result ≥ 1+ in the presence of normal serum glucose (\<120 mg/dL) at time of screening;~* A confirmed Grade ≥ 3 toxicity on any screening evaluations;~* Known allergy/sensitivity to the study agent or its components;~* Concurrent participation in an HIV vaccine study or other investigational drug study, including oral or topical PrEP (microbicide) studies;~* Use of disallowed medications; or~* Inability to understand spoken English.

- Gender: MALE
- Minimum Age: 15 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- PCC Behavioral Intervention Group (Type: EXPERIMENTAL): PCC Behavioral Intervention combined with open label FTC/TDF (Truvada®) as PrEP

Based on this trial design, predict the completion outcome and termination type (if applicable).